Celon Pharma at the GPW Innovation Day 2020

The GPW Innovation Day is a free-access conference during which representatives of companies operating in the field of new technologies, games or biotechnology meet with stock investors. This year, it will be held on-line on 23 and 24 June 2020. In the previous edition of the conference, the company presentations were participated by over 300Read more »

Celon Pharma at BIO Digital 2020

Company representatives will participate  in one of the largest partnering conferences for the biopharmaceutical industry, which will be held on 8-11.06.2020. During online sessions they will present selected projects in the therapeutic areas such as: neuropsychiatry, inflammatory and metabolic diseases. If you are interested in meeting with the Company, please contact: [email protected] More information aboutRead more »

The largest and most advanced innovative pipeline in Poland with the potential for global commercialisation, supported by a favourable domestic and worldwide dynamic of product sales.

Net profit of over PLN 9.4 million in Q1 2020, increase in domestic sales by 16% and by 2% in export sales, compared to the same period in 2019. In the first quarter of 2020, the value of sales revenues amounted to PLN 30.9 million. It included the product sales in Poland, which accounted forRead more »

4th project in clinical development – GPR40 with the consent of URPLWMiPB to launch the study

On 29 April 2020, we have received a positive decision from the Polish Office for Registration of Medicinal Products, Medical Devices and Biocidal Products (URPLWMiPB) regarding an innovative GPR40 receptor agonist – CLP207280. The clinical programme will be conducted in the treatment of metabolic diseases, including type II diabetes and diabetic neuropathies. The aim ofRead more »

Celon Pharma signs an agreement with the National Centre for Research and Development (NCRD) for subsidising the Company’s subsequent projects

“Serotonergic analgesic therapy based on5-HT7 receptor agonist (STEP7)” is a project constituting a part of our innovative pipeline, implemented in the field of neuropsychiatry. The goal of the STEP7 project is the development and clinical evaluation up to and including phase II studies, of a first-in-class 5-HT7 receptor agonist as an analgesic used in treatmentRead more »